tiprankstipranks
Halma PLC (GB:HLMA)
LSE:HLMA
Want to see GB:HLMA full AI Analyst Report?

Halma plc (HLMA) AI Stock Analysis

89 Followers

Top Page

GB:HLMA

Halma plc

(LSE:HLMA)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 5.2)
Rating:60Neutral
Price Target:
3,822.00 p
▼(-15.41% Downside)
Action:Downgraded
Date:07/11/26
The score is anchored by strong underlying financial performance (growth, profitability, moderate leverage, and solid free-cash-flow generation), but it is materially offset by weak technicals (downtrend across major moving averages and negative MACD) and a stretched valuation (high P/E with low yield).
Positive Factors
Consistent Revenue Growth
Consistent multi-year revenue growth, with a step-up in 2026, indicates durable end-market demand across safety, environmental and healthcare niches. Sustained top-line expansion supports operating leverage, funds reinvestment and organic M&A, and underpins medium-term profit and cash generation.
Negative Factors
Operating Cash Flow Volatility
Operating cash flow volatility and years where OCF lagged operating profit point to working-capital and timing swings. Persistent variability can complicate forecasting, increase financing needs in troughs and weaken the reliability of cash-backed returns or funding for discretionary investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Consistent multi-year revenue growth, with a step-up in 2026, indicates durable end-market demand across safety, environmental and healthcare niches. Sustained top-line expansion supports operating leverage, funds reinvestment and organic M&A, and underpins medium-term profit and cash generation.
Read all positive factors

Halma plc (HLMA) vs. iShares MSCI United Kingdom ETF (EWC)

Halma plc Business Overview & Revenue Model

Company Description
Halma plc, a company established in 1894 and headquartered in Amersham, United Kingdom, specializes in delivering innovative technological solutions across critical safety, health, and environmental sectors. Its operations are organized into three...
How the Company Makes Money
Halma primarily makes money by selling products and solutions from its portfolio of operating companies, with revenue recognized from the manufacture and sale of equipment and devices to customers across industrial, environmental, infrastructure a...

Halma plc Earnings Call Summary

Earnings Call Date:Nov 20, 2025
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Nov 19, 2026
Earnings Call Sentiment Positive
The earnings call presented a strong performance by Halma, with record half-year results, robust growth across sectors, significant investments, and a strong balance sheet. However, challenges such as cash conversion being below KPI and currency headwinds were noted. The strong positive aspects significantly outweighed the lowlights.
Positive Updates
Record Half-Year Results
Halma reported another set of record half-year results for Fiscal Year 2026, with headline revenue growth of 15% and EBIT growth of 27%. Organic growth was strong across all sectors, particularly in Photonics.
Negative Updates
Cash Conversion Below KPI
Cash conversion was below the KPI at 79%, due to substantial investments in R&D, acquisitions, and working capital.
Read all updates
Q2-2026 Updates
Negative
Record Half-Year Results
Halma reported another set of record half-year results for Fiscal Year 2026, with headline revenue growth of 15% and EBIT growth of 27%. Organic growth was strong across all sectors, particularly in Photonics.
Read all positive updates
Company Guidance
During the call, Halma reported strong financial results for the first half of the fiscal year 2026, driven by a diverse range of performance metrics across its sectors. The company achieved 15% headline revenue growth and a 27% increase in EBIT, with an organic revenue growth rate of 16.7%. Photonics significantly contributed to this growth, accounting for half of the organic increase. Halma maintained a robust margin of 22.3%, up by 160 basis points, and achieved a 16.2% return on capital, an increase of 190 basis points. Strategic investments totaled GBP 300 million, including GBP 60 million in R&D and GBP 130 million in acquisitions, supporting future growth. Despite a lower cash conversion rate of 79%, the company expects to align with its 90% KPI by year-end. Notably, Safety sector margins reached a historic high of 27%, with a 280 basis point increase. The Environmental & Analysis sector, excluding a one-off benefit, saw organic revenue and profit growth of 36% and 38%, respectively. Halma also upgraded its full-year guidance, anticipating mid-teens percentage organic constant currency revenue growth and an adjusted EBIT margin of around 22%.

Halma plc Financial Statement Overview

Summary
Fundamentals are strong overall: consistent multi-year revenue growth, healthy operating and net margins, moderate leverage (debt/equity staying below ~0.5), and solid free-cash-flow conversion. Main drawbacks are operating cash flow variability versus profit and an apparent data gap (latest-year gross profit/margin shown as zero) that reduces confidence in recent cost/margin visibility.
Income Statement
86
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
BreakdownMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.58B2.25B2.03B1.85B1.53B
Gross Profit1.29B1.13B1.01B877.90M724.30M
EBITDA656.80M537.30M475.50M410.60M373.40M
Net Income372.30M296.40M268.80M234.50M244.40M
Balance Sheet
Total Assets3.71B3.26B3.00B2.79B2.20B
Cash, Cash Equivalents and Short-Term Investments143.40M313.20M142.70M169.50M157.40M
Total Debt913.40M849.00M795.90M766.20M432.20M
Total Liabilities1.54B1.36B1.26B1.19B792.80M
Stockholders Equity2.17B1.90B1.74B1.60B1.40B
Cash Flow
Free Cash Flow398.90M433.00M333.40M195.30M189.40M
Operating Cash Flow453.80M492.40M385.00M241.20M229.40M
Investing Cash Flow-504.70M-163.90M-286.30M-369.60M-134.90M
Financing Cash Flow-121.10M-155.10M-119.70M138.50M-73.70M

Halma plc Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4518.00
Price Trends
50DMA
4183.67
Negative
100DMA
4128.05
Negative
200DMA
3842.14
Negative
Market Momentum
MACD
-151.52
Negative
RSI
37.29
Neutral
STOCH
45.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HLMA, the sentiment is Negative. The current price of 4518 is above the 20-day moving average (MA) of 3789.92, above the 50-day MA of 4183.67, and above the 200-day MA of 3842.14, indicating a bearish trend. The MACD of -151.52 indicates Negative momentum. The RSI at 37.29 is Neutral, neither overbought nor oversold. The STOCH value of 45.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:HLMA.

Halma plc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
£9.71B51.3518.55%1.13%13.31%13.05%
73
Outperform
£8.93B26.5831.07%3.44%1.13%1.73%
73
Outperform
£7.59B33.2613.71%1.93%-31.27%-13.26%
71
Outperform
£7.06B29.1024.91%1.29%4.25%29.89%
64
Neutral
£3.12B19.1611.55%3.58%-0.77%6.65%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
60
Neutral
£13.88B37.5117.92%0.67%14.87%25.57%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:HLMA
Halma plc
3,676.00
458.56
14.25%
GB:DPLM
Diploma
7,240.00
2,125.13
41.55%
GB:RS1
RS Group PLC
670.50
114.67
20.63%
GB:IMI
IMI plc
2,968.00
813.71
37.77%
GB:ITRK
Intertek
5,820.00
1,092.20
23.10%
GB:SMIN
Smiths Group plc
2,561.00
245.38
10.60%

Halma plc Corporate Events

Business Operations and StrategyM&A Transactions
Halma expands healthcare portfolio with acquisition of Dreampath Diagnostics
Positive
Jul 7, 2026
Halma has agreed to acquire Strasbourg-based Dreampath Diagnostics, a leading provider of automated systems for tracking, storing and managing patient tissue samples in anatomical pathology labs. Dreampath’s closed-system platform integrates...
Business Operations and StrategyM&A Transactions
Halma boosts healthcare portfolio with digital and oncology acquisitions
Positive
Jul 2, 2026
Halma plc has strengthened its healthcare portfolio with the bolt‑on acquisitions of Dutch firm itemedical and Sweden’s Naslund Medical, aligning with its strategy to grow in specialist, life‑saving technology markets. The deals ...
Business Operations and StrategyRegulatory Filings and Compliance
Halma executives vest share awards and sell stock to cover tax
Neutral
Jun 29, 2026
Halma has disclosed a series of share transactions by senior executives, including Group Chief Executive Marc Ronchetti and other sector leaders, involving the vesting of awards under its Executive Share Plan. Following vesting on 24 and 26 June, ...
Executive/Board Changes
Halma grants executive share awards to senior leadership team
Positive
Jun 29, 2026
Halma plc has awarded new share-based incentives to several senior executives under its Executive Share Plan, including Group Chief Executive Marc Ronchetti, Chief Financial Officer Carole Cran and other sector chiefs. The grants, made as performa...
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Halma Publishes 2026 Annual Report and AGM Notice for Investors
Positive
Jun 24, 2026
Halma plc, a FTSE 100‑listed global group of life‑saving technology companies, focuses on safety, environmental and analytical solutions, and healthcare technologies that protect people, critical infrastructure and natural resources wh...
Regulatory Filings and Compliance
Halma discloses share sale by senior sustainability and environmental chief
Neutral
Jun 23, 2026
Halma plc has disclosed that Constance Baroudel, Sector Chief Executive for Environmental Analysis and Chief Sustainability Officer, has sold 17,530 ordinary shares in the company. The transaction, conducted on 22 June 2026 on the London Stock Ex...
Regulatory Filings and Compliance
Halma director Sharmila Nebhrajani increases holding with £10,000 share purchase
Positive
Jun 16, 2026
Halma plc has disclosed a share purchase by independent non-executive director Sharmila Nebhrajani, in line with regulatory requirements for transactions by senior insiders. Nebhrajani acquired 248 ordinary shares in the company on 15 June 2026 on...
Business Operations and StrategyExecutive/Board Changes
Halma Non-Executive Director Sharmila Nebhrajani to Join Essentra Board
Positive
Jun 16, 2026
Halma has announced that non-executive director Sharmila Nebhrajani OBE will join the board of Essentra as a non-executive director from 29 June 2026, reflecting her growing external governance profile. The additional appointment may broaden Nebhr...
Executive/Board Changes
Halma refreshes board roles as long‑serving director Jo Harlow steps down
Neutral
Jun 12, 2026
Halma announced that non-executive director Jo Harlow will step down from the board at the conclusion of its 23 July 2026 annual general meeting, ending a nine-year tenure. The move continues the company’s planned board refresh as it maintai...
DividendsFinancial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Halma lifts final dividend as it posts full‑year 2026 results
Positive
Jun 11, 2026
Halma has reported its full‑year results for the 12 months to 31 March 2026 and confirmed that detailed financial information, including a webcast presentation and annual reports, is available on its corporate website and via the UK financia...
Business Operations and StrategyExecutive/Board Changes
Halma reshapes executive board as sector chiefs rotate roles
Positive
May 28, 2026
Halma has announced changes to its senior leadership, with Environmental Analysis Sector Chief Executive Constance Baroudel set to leave at the end of August 2026 to become chief executive of Spectris. She will be succeeded on 1 September 2026 by...
Business Operations and StrategyM&A Transactions
Halma expands ophthalmic portfolio with $90m Surgistar acquisition
Positive
Apr 13, 2026
Halma has acquired California‑based Surgistar, Inc., a specialist designer and manufacturer of ophthalmic surgical instruments such as blades, cannulas and trephines, for $90m in cash on a debt‑free, cash‑free basis funded from e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 11, 2026